The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancer

Not Applicable

• Conditions: inoperable advance and recurrence stomach and colon cancer combined with IgG1 antibody in chemotherapy

• Registration Number: JPRN-UMIN000013378
• Lead Sponsor: Kyoto Prefectural University of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

Not provided

Exclusion Criteria

1) Presence of uncontrolled infection 2) Hypersensitivity or autoimmune disease requiring treatments 3) Presence of severe comlications(malignant hypertension, congestive heart failure, severe coronary disease, history of myocardial infarction less than six months prior, pulmonary fibrosis or active interstitial pneumonitis) 4) Inappropriate patients for this study due to severe complications. 5) Patient who cannot undergo enhanced CT scan or MRI due to some reason such as allergy for contrast media or renal dysfunction. 6) Active other malignancy, except lesions of "carcinoma in situ" or intramucosal location which are curatively resectable. 7) Medical history of severe hypersensitivity. 8) Severe mental impairment 9) Pregnant or lactating women 10) Patient with HBV, HCV, HIV, HTLV-1 or syphilis infection 11) Inappropriate patients for study judged by the physicians. 12) Patient with bad NK cell cultivation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified